Tag: 400-500

《Compatibility study of four binary combinations of active ingredients for dermal film forming systems》 was published in Farmacia (Bucharest, Romania) in 2020. These research results belong to Rusu, Aura; Ciurba, Adriana; Birsan, Magdalena; Antonoaea, Paula; Szekely-Szentmiklosi, Blanka; Fulop, Ibolya; Pascu, Giorgiana-Andreea; Todoran, Nicoleta. Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid The article mentions the following:

Adapalene (ADA), levofloxacin (LEV), meloxicam (MEL) and miconazole nitrate (MIC) were selected as potential active ingredients for film systems with dermal or transdermal delivery. This study aimed to evaluate the compatibility of four binary mixtures – ADA and LEV (M1), ADA and MIC (M2), LEV and MEL (M3), and LEV and MIC (M4) – combinations for new bioadhesive polymeric matrix dermal systems produced by the casting solvent evaporation technique. The Fourier-transform IR spectroscopy (FTIR), differential scanning calorimetry (DSC) and mol. modeling (MM) were used to characterize and evaluate the compatibility between the selected active substances. In the FTIR data, M1, M2, and M4 mixtures presented a good compatibility. DSC revealed different chem. interactions as the temperature rose above 160°C, especially for M3 and M4. Through MM technique, interactions were found on the M2 and M3 mixtures Following the correlation of all obtained results, the best compatibility was found to be on M1 and M4 combinations. The experimental part of the paper was very detailed, including the reaction process of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Sezaki, Maiko; Biswas, Subinoy; Nakata, Sayuri; Oshima, Motohiko; Koide, Shuhei; Ho, Nicole Pui Yu; Okamoto, Nobukazu; Miyamoto, Takeshi; Iwama, Atsushi; Takizawa, Hitoshi published an article in 2021. The article was titled 《CD271+CD51+PALLADIN- Human Mesenchymal Stromal Cells Possess Enhanced Ossicle-Forming Potential》, and you may find the article in Stem Cells and Development.Product Details of 106685-40-9 The information in the text is summarized as follows:

Human mesenchymal stem/stromal cells (hMSCs), when engrafted into immunodeficient mice, can form ectopic bone organs with hematopoietic stem cell (HSC) supportive functions. However, the ability to do so, through a cartilage intermediate, appears limited to 30% of donor bone marrow samples. In this study, we characterize the heterogeneous nature of hMSCs and their ability to efficiently form humanized ossicles observed in “”good donors”” to correlate with the frequency and functionality of chondrocyte progenitors. Flow cytometry of putative hMSC markers was enriched in the CD271+CD51+ stromal cell subset, which also possessed enhanced hMSC activity as assessed by single-cell colony-forming unit fibroblast (CFU-F) and undifferentiated mesensphere formation. Transcriptome anal. of CD271+ cells presented upregulation of chondrogenesis-/osteogenesis-related genes and HSC/niche maintenance factors such as C-X-C motif chemokine 12 (CXCL12) and ANGIOPOIETIN 1. Among the candidate genes selected to enrich for subsets with greater chondrogenic ability, cells neg. for the actin cross-linker PALLADIN displayed the greatest CFU-F potential. Our study contributes to a better characterization of ossicle-forming hMSCs and their efficient isolation for the optimized engineering of human bone organs. In the experiment, the researchers used many compounds, for example, 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Product Details of 106685-40-9)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.Product Details of 106685-40-9

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2022,Huang, Yunyuan; Xu, Haiyan; Wang, Pei; Gu, Rurong; Li, Xiaokang; Xu, Yixiang; Wang, Jiqun; Qiao, Sicong; Shi, Donglei; Gao, Zhaobing; Li, Jian published an article in ACS Chemical Neuroscience. The title of the article was 《Identification of Guaifenesin-Andrographolide as a Novel Combinatorial Drug Therapy for Epilepsy Using Network Virtual Screening and Experimental Validation》.Application of 106685-40-9 The author mentioned the following in the article:

Combinatorial drug therapy has attracted substantial attention as an emerging strategy for the treatment of diseases with complex pathol. mechanisms. We previously developed a potentially universal computational screening approach for combination drugs and used this approach to successfully identify some beneficial combinations for the treatment of heart failure. Herein, this screening approach was used to identify novel combination drugs for the treatment of epilepsy in an approved drug library. The combination of guaifenesin-andrographolide was first discovered as a promising therapy with synergistic anticonvulsant activities in maximal electroshock (MES)- and s.c. pentylenetetrazol (s.c.-PTZ)-induced epilepsy models in vivo. The studies of network anal., fluorescence imaging, and N-methyl-D-aspartate (NMDA)-induced cytotoxicity further revealed that guaifenesin-andrographolide might synergistically affect NMDA receptors and then alleviate the pathogenesis of epilepsy. Therefore, we report that the combination of guaifenesin-andrographolide exerts effects against epilepsy through a novel synergistic mechanism and is thus a potential treatment for epilepsy, providing a promising mechanism for the design of novel combinatorial drug treatments against epilepsy. The results came from multiple reactions, including the reaction of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Application of 106685-40-9)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.Application of 106685-40-9

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2022,Teunissen, M; Ahrens, N S; Snel, L; Narcisi, R; Kamali, S A; van Osch, G J V M; Meij, B P; Mastbergen, S C; Sivasubramaniyan, K; Tryfonidou, M A published an article in Stem cell research & therapy. The title of the article was 《Synovial membrane-derived mesenchymal progenitor cells from osteoarthritic joints in dogs possess lower chondrogenic-, and higher osteogenic capacity compared to normal joints.》.Quality Control of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid The author mentioned the following in the article:

BACKGROUND: Synovial membrane-derived mesenchymal progenitor cells (SM-MPCs) are a promising candidate for the cell-based treatment of osteoarthritis (OA) considering their in vitro and in vivo capacity for cartilage repair. However, the OA environment may adversely impact their regenerative capacity. There are no studies for canine (c)SM-MPCs that compare normal to OA SM-MPCs, even though dogs are considered a relevant animal model for OA. Therefore, this study compared cSM-MPCs from normal and OA synovial membrane tissue to elucidate the effect of the OA environment on MPC numbers, indicated by CD marker profile and colony-forming unit (CFU) capacity, and the impact of the OA niche on tri-lineage differentiation. METHODS: Normal and OA synovial membrane were collected from the knee joints of healthy dogs and dogs with rupture of the cruciate ligaments. The synovium was assessed by histopathological OARSI scoring and by RT-qPCR for inflammation/synovitis-related markers. The presence of cSM-MPCs in the native tissue was further characterized with flow cytometry, RT-qPCR, and immunohistochemistry, using the MPC markers; CD90, CD73, CD44, CD271, and CD34. Furthermore, cells isolated upon enzymatic digestion were characterized by CFU capacity, and a population doublings assay. cSM-MPCs were selected based on plastic adherence, expanded to passage 2, and evaluated for the expression of MPC-related surface markers and tri-lineage differentiation capacity. RESULTS: Synovial tissue collected from the OA joints had a significantly higher OARSI score compared to normal joints, and significantly upregulated inflammation/synovitis markers S100A8/9, IL6, IL8, and CCL2. Both normal and OA synovial membrane contained cells displaying MPC properties, including a fibroblast-like morphology, CFU capacity, and maintained MPC marker expression over time during expansion. However, OA cSM-MPCs were unable to differentiate towards the chondrogenic lineage and had low adipogenic capacity in contrast to normal cSM-MPCs, whereas they possessed a higher osteogenic capacity. Furthermore, the OA synovial membrane contained significantly lower percentages of CD90+, CD44+, CD34+, and CD271+ cells. CONCLUSIONS: The OA environment had adverse effects on the regenerative potential of cSM-MPCs, corroborated by decreased CFU, population doubling, and chondrogenic capacity compared to normal cSM-MPCs. OA cSM-MPCs may be a less optimal candidate for the cell-based treatment of OA than normal cSM-MPCs. In the experimental materials used by the author, we found 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Quality Control of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.Quality Control of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2019,Farmacia (Bucharest, Romania) included an article by Imre, Silvia; Al Hussein, Stela Mariana; Pascu, Andreea; Oltean, Laura Elena; Dogaru, Maria-Titica; Al Hussein, Hamida; Muntean, Daniela-Lucia; Tero-Vescan, Amelia. Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid. The article was titled 《Concomitant HPLC analysis of adapalene and nadifloxacin in the presence of glycolic acid》. The information in the text is summarized as follows:

Reversed phase HPLC-UV is the most common anal. method applied in pharmaceutical anal., but there are cases when its versatility is challenged, such as simultaneous separation of analytes with very different polarity and lipophilicity. A fast HPLC-UV method for the simultaneous determination of nadifloxacin (NDX) and adapalene (ADP) in the presence of glycolic acid (GA) was developed and anal. performances of the method were verified. Different alkane-type reversed phases (RP8 and RP18 columns, with different lengths and particle sizes) and different mobile phases were tested. Finally, a C18 column (33 x 4.6 mm, 3 mm) and a mobile phase consisted of 15 mM orthophosphoric acid solution and acetonitrile were selected. Determinations were performed with a run time of 4 min. The method was linear, accurate and precise over the selected concentration ranges of ADP and NDX. The developed method can be used for rapid quantification ADP and NDX without GA interference for in vitro release studies from topical formulations, through different types of diffusion membranes. In the experiment, the researchers used 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

The author of 《Optimization of nanostructured lipid carriers loaded with retinoids by central composite design》 were Pinto, Fatima; de Barros, Dragana P. C.; Reis, Catarina; Fonseca, Luis P.. And the article was published in Journal of Molecular Liquids in 2019. COA of Formula: C28H28O3 The author mentioned the following in the article:

The aim of this study was to design and optimize a new formulation of lipid nanoparticles for the topical administration of retinoids. The standard procedure involves nanostructured lipid carriers (NLCs) synthesized by the miniemulsion methodol., using sunflower oil as a bioactive ingredient and retinyl palmitate (RP) as model retinoid. A 5-factor, 3-level central composite design was used to predict responses and construct 3D-response contour plots. The independent variables were the concentration of total lipids, solid lipid, surfactant, encapsulated retinoid and number of carbons on the solid lipid fatty acid chain length, in function of the selected responses as the particle size, surface charge of the nanoparticles and the encapsulation efficiency (EE %) at 3 levels. Exptl. trials were performed at all 31 possible combinations. An optimized NLC composition of 2.5% total lipids, 2.0% myristic acid and 0.5% sunflower oil and 1.5% of surfactant Tween 80 was reached. DSC anal. indicated that the melting temperatures of the three optimized NLCs loaded with the retinoids were above 40°C, proving to be suitable for use in topical administration. The in vitro drug release studies were conducted for 48 h, using a dialysis regenerated cellulose membrane. The results demonstrated a very well-controlled release of RP and TRT, which improves the stability of these active compounds and confirms a high encapsulation efficiency. The results came from multiple reactions, including the reaction of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9COA of Formula: C28H28O3)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.COA of Formula: C28H28O3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2019,Pediatric dermatology included an article by Treesirichod, Arucha; Chaithirayanon, Suthida; Wongjitrat, Nattakarn. Related Products of 106685-40-9. The article was titled 《Comparison of the efficacy and safety of 0.1% adapalene gel and 0.025% tretinoin cream in the treatment of childhood acanthosis nigricans.》. The information in the text is summarized as follows:

BACKGROUND: There have been few published randomized controlled trials for the treatment of childhood acanthosis nigricans (AN) to date. OBJECTIVE: To assess the efficacy of topical 0.1% adapalene gel compared to 0.025% tretinoin cream in the treatment of childhood AN. METHODS: An 8-week, randomized, split-neck, comparative study between topical 0.1% adapalene gel and 0.025% tretinoin cream for the treatment of neck hyperpigmentation associated with AN was performed. M index measured by a narrowband reflectance spectrophotometer and both investigator’s global evaluation (IGE) and parent’s global evaluation (PGE) scales were used to evaluate efficacy. RESULTS: There was no statistically significant difference between 0.1% adapalene gel and 0.025% tretinoin cream in the treatment of AN-associated hyperpigmentation (P = 0.56). Mean differences in M indices between week 0 and week 8 of 0.1% adapalene and 0.025% tretinoin treatment were 24.2 ± 7.9% and 23.8 ± 8.3% improvement, respectively. Regarding treatment efficacy, 90.0% and 85.0% of participants had more than 75% improvement in IGE in 0.1% adapalene and 0.025% tretinoin treatment sides, respectively. In addition, 75.0% and 65.0% of participants had more than 75.0% improvement in PGE in 0.1% adapalene and 0.025% tretinoin treatment sides, respectively. LIMITATIONS: Lack of histopathological evaluations. CONCLUSIONS: We found no significant difference between topical 0.1% adapalene gel and 0.025% tretinoin in the treatment of AN.6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Related Products of 106685-40-9) was used in this study.

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Related Products of 106685-40-9

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

SDS of cas: 106685-40-9In 2019 ,《The role of topical retinoids in prevention and treatment of atropliic acne scarring: understanding the importance of early effective treatment》 appeared in Journal of Drugs in Dermatology. The author of the article were Tan, Jerry; Tanghetti, Emil; Baldwin, Hilary; Gold, Linda Stein; Lain, Edward. The article conveys some information:

A review. Atrophic acne scarring is a frequent occurrence among acne patients. These facial marks are often very emotionally distressing for the patient and can result in adverse impact to quality of life. While most clinicians consider scarring as a sequela of moderate to severe acne, recent studies have found that scars are also associated with mild acne. Risk factors include time to effective treatment, severity of acne, family history, and excoriations. New data shows that early and effective acne treatment can reduce the development of new scars, confirming the widespread perception of this approach in prevention. It is also becoming clear that the inflammatery process drives both the development of acne lesions and atrophic scars. This implies that inhibiting activation of inflammatory pathways early is key to preventing scars. Data also suggests a useful role for adapalene for the treatment of well-established acne scars with scar remodeling accompanied by the production of new collagen and elastic tissue. Acne guidelines and recommendations continue to highlight the central role of retinoids, with fixed-dose combination retinoids being particularly important due to targeting of multiple inflammatory pathophysiol. factors and for patient convenience. Higher concentrations of retinoids such as adapalene 0.3%/benzoyl peroxide 2.5% (A0.3/BPO2.5) have shown increased efficacy, particularly among patients with moderately severe and severe acne – a population at high risk for scarring. Further, controlled study of A0.3/BP02.5 in patients with moderate acne (mean, 40 acne lesions per half face) and mild-moderate scarring demonstrated A0.3/BPO2.5 was significantly superior to vehicle in reducing scar counts from baseline over 24 wk. While scar counts lessened on the A0.3/BPO2.5 side, counts increased on the vehicle side during the study. This occurred in the setting of active acne, where the efficacy of A/BPO is well known, emphasizing the dual actions of A0.3/BPO2.5 in both treatment and prevention. The experimental part of the paper was very detailed, including the reaction process of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9SDS of cas: 106685-40-9)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.SDS of cas: 106685-40-9

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acidIn 2021 ,《Meningeal Multipotent Cells: A Hidden Target for CNS Repair》 appeared in NeuroMolecular Medicine. The author of the article were Hayakawa, Kazuhide; Snyder, Evan Y.; Lo, Eng H.. The article conveys some information:

A review. Abstract: Traditionally, the primary role of the meninges is thought to be structural, i.e., to act as a surrounding membrane that contains and cushions the brain with cerebrospinal fluid. During development, the meninges is formed by both mesenchymal and neural crest cells. There is now emerging evidence that subsets of undifferentiated stem cells might persist in the adult meninges. In this mini-review, we survey representative studies of brain-meningeal interactions and discuss the hypothesis that the meninges are not just protective membranes, but instead contain multiplex stem cell subsets that may contribute to central nervous system (CNS) homeostasis. Further investigations into meningeal multipotent cells may reveal a “”hidden”” target for promoting neurovascular remodeling and repair after CNS injury and disease. After reading the article, we found that the author used 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acidIn 2019 ,《Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized, split-face, open-label, single-center study》 was published in Cutaneous and Ocular Toxicology. The article was written by Zheng, Yue; Yin, Songchao; Xia, Yue; Chen, Jian; Ye, Congxiu; Zeng, Quanrong; Lai, Wei. The article contains the following contents:

Topical drugs for mild to moderate acne include adapalene (ADA) and benzoyl peroxide(BPO). Supramol. salicylic acid (SSA), a modified SA preparation, is considered as a new effective therapeutic scheme. To compare the safety and efficacy of 2% supramol. SA (2% SSA) with 0.01% adapalene plus 5% benzoyl peroxide (5%BPO +0.1%ADA) for treatment of facial acne. This was an open-label, split face, randomized and single-center clin. trial. Subjects with mild to moderate acne were enrolled. Two percent SSA cream were randomly applied on one side of the face while 5%BPO +0.1%ADA gel was applied on the opposite side for 28 days. The numbers of acne lesions, along with side effects of the targeted area were evaluated by the investigators at day 0, day 14, and day 28. Skin water content, TEWL and skin lightening indexes were measured at the same time. A total of 31 of acne patients completed the trial. Dates showed that 2% SSA had similar effects to 5%BPO +0.1%ADA in reducing papules/pustules (47.9% vs. 49.8%), non-inflammatory lesions (43.1% vs. 42.7%) and total lesions (44.1% vs. 45.6%; all p > 0.05) at day 28. The skin barrier (skin hydration value and TEWL value), skin brightness (L* value) and erythema (a* values) indicators showed no statistical differences in the left and right sides of the face (p > 0.05). This study demonstrated that 2% SSA has a similar efficacy with 5%BPO +0.1%ADA in mild to moderate acne treatment. This might be a useful pilot study that could be used to support further larger clin. trials. The experimental process involved the reaction of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem